K100560

MAY 12 2010

510(k) Summary (Per 21 CFR 807.92)

Updated on April 6, 2010

1. Submitter Information

Company name	Biotest Medical Corporation
Contact person	Maggie Chu, President
Address	No. 3-2, Chien-Kuo Road, TEPZ, Tantzu Taichung 427, Taiwan Republic of China
Phone	886-919099431
Fax	886-425326593

2. Name of Device

Trade Name	Easy Talk Blood Glucose Monitoring System
Common Name	Blood Glucose Test System
Classifications	NBW, Over the Counter Blood Glucose Test, 862.1345 CGA, Glucose Oxidase, 862.1345 Class II device

3. Predicate Device

Trade name	SuperCheck 1 Blood Glucose Monitoring System (SuperCheck 1), Model 6268
Common name	Blood Glucose Test System
Submitter	Biotest Medical Corporation
510(k) number	K091815

4. Device Description

The Easy Talk Blood Glucose Monitoring System, consists of a blood glucose meter, test strips, control solutions, lancing device, and commercially available lancets. The meter has a bilingual speaking feature that provides audible test results for users with low vision. The forearm may be used as an alternate site for capillary blood.

5. Intended Use

The Easy Talk Blood Glucose Monitoring System, is intended for use in the quantitative measurement of glucose in fresh capillary whole blood from the finger and the forearm. It is intended for use by healthcare professionals and people with diabetes mellitus at home and as an aid in monitoring the effectiveness of a diabetes control program. It is not intended for the diagnosis or screening for diabetes mellitus, nor for use with neonates.

The alternative site testing (forearm) in this system can only be used during steady-state blood glucose conditions.

This system contains a speaking function that provides audible test results for users with low vision.

6. Comparison to Predicate Device

Modifications to the cleared device include additional backlight feature and change of one error message from E_7 to E_4. The size and shape of the device have also been modified to differentiate from the predicate. The Easy Talk Blood Glucose Monitoring System has the same indented use and fundamental scientific technology as the previous version, the SuperCheck 1 Blood Glucose Monitoring System, Model 6268.

7. Performance Studies

Non-clinical Tests

Biotest Medical Corp. has performed the extensive verification, validation and testing activities to establish the performance, functionality and reliability characteristics of the device. The device passed all of the tests based on pre-determined Pass/Fail criteria.

Clinical Tests

The clinical performance study was conducted for purpose of validating consumer's use of the Easy Talk Blood Glucose Monitoring System in term of usability and accuracy. The test results showed substantial equivalence.

8. Conclusion

The conclusion drawn from the non-clinical and clinical tests is that the Easy Talk Blood Glucose Monitoring System is as safe, as effective, and performs as well as the legally marketed predicate device, SuperCheck 1 Blood Glucose Monitoring System, model 6268 (k091815). Therefore, the subject device is substantially equivalent to the predicate device.

DEPARTMENT OF HEALTH & HUMAN SERVICES

Food and Drug Administration
10903 New Hampshire Avenue
Document Mail Center – WO66-0609
Silver Spring, MD 20993-0002

Biotest Medical Corporation
c/o Maggie Chu
President
No. 3-2, Chien-Kuo Road, TEPZ, Tantzu
Taichung, China (Taiwan) 427

MAY 12 2010

Re: k100560
Trade/Device Name: Easy Talk Blood Glucose Monitoring System, Model: 6277
Regulation Number: 21 CFR 862.1345
Regulation Name: Glucose Test System
Regulatory Class: Class II
Product Code: NBW, CGA
Dated: April 12, 2010
Received: April 14, 2010

Dear Ms. Chu

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in Title 21, Code of Federal Regulations (CFR), Parts 800 to 895. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Parts 801 and 809); and good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820).

This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Office of *In Vitro* Diagnostic Device Evaluation and Safety at (301) 796-5450. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding postmarket surveillance, please contact CDRH's Office of Surveillance and Biometric's (OSB's) Division of Postmarket Surveillance at (301) 796-5760. For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.

You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 796-5680 or at its Internet address http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm.

Sincerely yours,

Courtney C. Harper, Ph.D.
Director
Division of Chemistry and Toxicology
Office of *In Vitro* Diagnostic Device
Evaluation and Safety
Center for Devices and Radiological Health

Enclosure

Indications for Use

510(k) Number (if known): K100560

Device Name: Easy Talk Blood Glucose Monitoring System

Indications for Use:

The Easy Talk Blood Glucose Monitoring System, is intended for use in the quantitative measurement of glucose in fresh capillary whole blood from the finger and the forearm. It is intended for use by healthcare professionals and people with diabetes mellitus at home and as an aid in monitoring the effectiveness of a diabetes control program. It is not intended for the diagnosis or screening for diabetes mellitus, nor for use with neonates.

The alternative site testing (forearm) in this system can only be used during steady-state blood glucose conditions.

This system contains a speaking function that provides audible test results for users with low vision.

Prescription Use __X_____ (Part 21 CFR 801 Subpart D)	AND/OR	Over-The-Counter Use __X___ (21 CFR 801 Subpart C)

(PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE OF NEEDED)

Concurrence of CDRH, Office of In Vitro Diagnostic Devices (OIVD)

Division Sign-Off
Office of In Vitro Diagnostic Device
Evaluation and Safety

510(k) K100560